- Home
- SNSE vs CARM Comparison
SNSE vs CARM Comparison
Compare SNSE & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- CARM
- Stock Information
- Founded
- SNSE 2005
- CARM 2016
- Country
- SNSE United States
- CARM United States
- Employees
- SNSE N/A
- CARM N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- CARM Health Care
- Exchange
- SNSE Nasdaq
- CARM Nasdaq
- Market Cap
- SNSE 10.2M
- CARM 12.2M
- IPO Year
- SNSE 2021
- CARM N/A
- Fundamental
- Price
- SNSE $8.81
- CARM $0.32
- Analyst Decision
- SNSE Strong Buy
- CARM Hold
- Analyst Count
- SNSE 4
- CARM 5
- Target Price
- SNSE $72.50
- CARM $0.90
- AVG Volume (30 Days)
- SNSE 16.6K
- CARM 24.8M
- Earning Date
- SNSE 08-05-2025
- CARM 08-07-2025
- Dividend Yield
- SNSE N/A
- CARM N/A
- EPS Growth
- SNSE N/A
- CARM N/A
- EPS
- SNSE N/A
- CARM N/A
- Revenue
- SNSE N/A
- CARM $10,767,000.00
- Revenue This Year
- SNSE N/A
- CARM N/A
- Revenue Next Year
- SNSE N/A
- CARM N/A
- P/E Ratio
- SNSE N/A
- CARM N/A
- Revenue Growth
- SNSE N/A
- CARM N/A
- 52 Week Low
- SNSE $5.00
- CARM $0.14
- 52 Week High
- SNSE $17.40
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- SNSE 58.00
- CARM 52.65
- Support Level
- SNSE $7.79
- CARM $0.21
- Resistance Level
- SNSE $8.69
- CARM $0.56
- Average True Range (ATR)
- SNSE 0.73
- CARM 0.04
- MACD
- SNSE 0.08
- CARM 0.02
- Stochastic Oscillator
- SNSE 79.72
- CARM 31.79
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.